Skip to main content
NCBI home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1999 Oct;90(10):1130–1138. doi: 10.1111/j.1349-7006.1999.tb00687.x

Effectiveness of a Simply Designed Tumor Vaccine in Prevention of Malignant Melanoma Development

Srdjan Novakovic 1,3,✉, Alojz Ihan 2, Barbara Jezereks 1,✉
PMCID: PMC5926005  PMID: 10595742

Abstract

We investigated the efficacy of a simple syngeneic tumor vaccine to induce specific antitumor immunity in female C57B1/6 mice. Tumor vaccine was prepared by mixing irradiated B‐16 melanoma tumor cells with the pleiotropic biological response modifier—maleic anhydride divinyl ether (MVE‐2). Experimental animals were pretreated with the vaccine in order to prevent the development of intraperitoneal (i.p.) B‐16 melanoma tumors after inoculation of viable tumor cells. More than 40% of prevaccinated animals challenged i.p. with 5×105 viable tumor cells were completely protected from tumor development and remained tumor‐free 100 days after tumor cell inoculation. The percentage of tumor‐free animals (survivors) rose to as much as 90% when the application of tumor vaccine was repeated two weeks after the first vaccination (i.e. one week after the inoculation of viable tumor cells). The induced antitumor response depended predominantly upon macro‐phage function, since vaccinated animals which were depleted of peritoneal macrophages died within the same time range as animals in the control group. Also, tumor‐type specificity of the vaccine was confirmed by the fact that the animals vaccinated with B‐16 melanoma vaccine were not protected from the development of another type of tumor. In conclusion, comparison of the experimental data with the data from the literature suggests that our simple tumor vaccine may be as effective as genetically engineered tumor vaccines. At the same time, this kind of vaccine is easier to control and thus safer to apply in humans when compared to genetically engineered vaccines.

Keywords: Cancer, Prevention, Tumor vaccine, Melanoma

Full Text

The Full Text of this article is available as a PDF (138.9 KB).

REFERENCES

  • 1. ) Oettgen , H. and Old , L. J.The history of cancer immunotherapy . In“Biologic Therapy of Cancer ” ed. V. T. De Vita , Hellman S. and Rosenberg S. A. , pp. 53 – 66 ( 1991. ). Lippincott; , Philadelphia . [Google Scholar]
  • 2. ) Novakovic , S. , Menart , V. , Gaberc‐Porekar , V. , Talc , A. , Sera , G. , Emazar , M. and Jezersek , B.New TNF‐α analogues: a powerful but less toxic biological tool against tumors . Cytokine , 8 , 597 – 604 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Novakovi , S.Current approaches to gene therapy in oncology: construction of tumor vaccines . Radiol. Oncol., Effectiveness of a Simply Designed Tumor Vaccine 30 , 260 , 267 ( 1996. ) [Google Scholar]
  • 4. ) Zwiebel , A. J. , Su , N. , MacPherson , A. , Davis , T. and Ojeifo , O. J.The gene therapy of cancer: transgenic immunotherapy . Semin. Hematol. , 30 , 119 – 129 ( 1993. ). [PubMed] [Google Scholar]
  • 5. ) Allione , A. , Consalvo , M. , Nanni , P. , Lollini , L. P. , Cavallo , F. , Giovarelli , M. , Forni , M. , Gulino , A. , Colombo , P. M. , Dellabona , P. , Hock , H. , Blankenstein , T. , Rosenthal , M. F. , Gansbacher , B. , Bosco , C. M. , Musso , T. , Gusella , L. and Forni , G.Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)‐2, IL‐4, IL‐6, IL‐7, IL‐10, tumor necrosis factor α, granulocyte‐macrophage colony‐stimulating factor, and γ‐interferon gene or admixed with conventional adjuvants . Cancer Res. , 54 , 6022 – 6026 ( 1994. ). [PubMed] [Google Scholar]
  • 6. ) Dranoff , G. , Jaffee , E. , Lazenby , A. , Golumbek , P. , Levitsky , H. , Brose , K. , Jackson , V. , Hamada , H. , Pardoll , D. and Mulligan , C. R.Vaccination with irradiated tumor cells engineered to secrete murine GM‐CSF stimulates potent, specific and long lasting anti‐tumor immunity . Proc. Natl. Acad. Sci. USA , 90 , 3539 – 3543 ( 1993. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. ) Gansbacher , B. , Zier , K. , Daniels , B. , Cronin , K. , Bannerji , R. and Gilboa , E.Interleukin‐2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity . J. Exp. Med. , 172 , 1217 – 1224 ( 1990. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. ) Russell , S. J. , Eccles , S. A. , Flemming , C. L. , Johnson , C. A. and Collins , M. K. L.Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL‐2 cDNA . Int. J. Cancer , 47 , 244 – 251 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 9. ) Plaksin , D. , Porgador , A. , Vadai , E. , Feldman , M. , Schirrmacher , V. and Eisenbach , L.Effective anti‐meta‐static melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV) . Int. J. Cancer , 59 , 796 – 801 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 10. ) Townsend , S. E. and Allison , J. P.Tumor rejection after direct costimulation of CD8+ T cells by B7‐transfected melanoma cells . Science , 259 , 368 – 370 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 11. ) Townsend , S. E. , Su , F. W. , Atherton , J. M. and Allison , J. P.Specificity and longevity of antitumor immune response induced by B7‐transfected tumors . Cancer Res. , 54 , 6477 – 6483 ( 1994. ). [PubMed] [Google Scholar]
  • 12. ) Drazan , E. K. , Shen , D. X. , Csete , E. M. , Zhang , W. W. , Roth , A. J. , Busuttil , W. R. and Shaked , A.In vivo adenoviral‐mediated human p53 tumor suppressor gene transfer and expression in rat liver after resection . Surgery , 116 , 197 – 204 ( 1994. ). [PubMed] [Google Scholar]
  • 13. ) Roth , A. J. , Mukhopadhyay , T. , Zhang , W. W. , Fujiwara , T. and Georges , R.Gene replacement strategies for the prevention and therapy of cancer . In“The Internet Book of Gene Therapy/Cancer Therapeutics ” ed. Sobol E. R. and Scanlon J. K. , pp. 229 – 233 ( 1995. ). Appleton & Lange; , Stamford . [Google Scholar]
  • 14. ) Moolten , F. L. and Wells , J. M.Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors . J. Natl. Cancer Inst. , 82 , 297 – 300 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 15. ) Moolten , F. L.Drug sensitivity (“suicide”) genes for selective cancer chemotherapy . Cancer Gene Ther. , 1 , 279 – 287 ( 1994. ). [PubMed] [Google Scholar]
  • 16. ) Sobol , E. R. and Scanlon , J. K.“The Internet Book of Gene Therapy/Cancer Therapeutics” ( 1995. ). Appleton & Lange; , Stamford . [Google Scholar]
  • 17. ) Budzynski , W. , Chirigos , M. and Gruys , E.Augmentation of natural cell activity in tumor‐bearing and normal mice by MVE‐2 . Cancer Immunol. Immunother. , 24 , 253 – 258 ( 1987. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. ) Salup , R. R. , Herberman , R. B. , Chirigos , M. A. , Back , T. and Wiltrout , R. H.Therapy of peritoneal murine cancer with biological response modifiers . J. Immunopharmacol. , 7 , 417 – 436 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 19. ) Wallace , P. K. and Morahan , P. S.Role of macrophages in the immunotherapy of Lewis lung peritoneal carcinomatosis . J. Leukoc. Biol. , 56 , 41 – 51 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 20. ) Belardelli , F. , Gresser , I. , Maury , C. and Maunoury , M. T.Antitumor effects of interferon in mice injected with interferon‐sensitive and interferon‐resistant Friend leukemia cells. II. Role of host mechanisms . Int. J. Cancer , 30 , 821 – 825 ( 1982. ). [DOI] [PubMed] [Google Scholar]
  • 21. ) Hock , H. , Dorsch , M. , Kunzendorf , U. , Quin , Z. , Diamantstein , T. and Blankenstein , T.Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant . Cancer Res. , 53 , 1 – 3 ( 1993. ). [PubMed] [Google Scholar]
  • 22. ) Scaringi , L. , Tissi , L. , Cornacchione , P. , Rosati , E. , Campanelli , C. , von Hunolstein , C. , Orefici , G. , Rossi , R. and Marconi , P.Antibody‐independent protection in mice against type Ia group B streptococcus lethal infection . FEMS Immunol. Med. Microbiol. , 9 , 151 – 162 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 23. ) Morahan , P. S. , Pinto , A. , Stewart , D. , Murasco , D. M. and Brinton , M. A.Varying role of alpha/beta interferon in the antiviral efficacy of synthetic immunomodulators against Semliki Forrest virus infection . Antiviral Res. , 15 , 241 – 254 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 24. ) Piccoli , M. , Saito , T. and Chirigos , M. A.Bimodal effects of MVE‐2 on cytotoxic activity of natural killer cell and macrophage tumoricidal activities . Int. J. Immunopharmacol. , 6 , 569 – 576 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 25. ) Rios , A. , Rosenblum , M. , Powell , M. and Hersh , E.Phase I study of MVE‐2 therapy in human cancer . Cancer Treat. Rep. , 67 , 239 – 243 ( 1983. ). [PubMed] [Google Scholar]
  • 26. ) Shlick , E. , Ruffmann , R. , Hartung , K. and Chirigos , M. A.Modulation of myelopoiesis by CSF or CSF‐inducing biological response modifiers . J. Immunopharmacol. , 7 , 141 – 166 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 27. ) Kaneda , Y. , Yamamoto , Y. , Tsunoda , S. , Kamida , H. , Tsutsumi , Y. , Hirano , T. and Mayumi , T.Bioconjugation of tumor necrosis factor‐alpha with the copolymer of divinyl ether and maleic anhydride increasing its antitumor potency . Biochem. Biophys. Res. Commun. , 239 , 160 – 165 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 28. ) Yamamoto , H. , Miki , T. , Oda , T. , Hirano , T. , Sera , Y. , Akagi , M. and Maeda , H.Reduced bone marrow toxicity of neocarzinostatin by conjugation with divinyl ether maleic acid copolymer . Eur. J. Cancer , 26 , 253 – 260 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 29. ) Blankenstein , T. , Qin , Z. , überla , K. , Müller , W. , Rosen , H. , Volk , H. D. and Diamantstein , T.Tumor suppression after tumor cell‐targeted tumor necrosis factor α gene transfer . J. Exp. Med. , 173 , 1047 – 1052 ( 1991. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. ) Schirrmacher , V.Biotherapy of cancer/perspectives of immunotherapy and gene therapy . J. Cancer Res. Clin. Oncol. , 121 , 443 – 451 ( 1995. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. ) Guo , Y. J. , Che , X. Y. , Shen , F. , Ma , J. , Wang , X. N. , Wu , S. G. , Anthony , D. D. and Wu , C. M.Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies . Nat. Med. , 3 , 451 – 455 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 32. ) Sampson , H. J. , Archer , E. G. , Ashley , M. D. , Fuchs , E. H. , Hale , P. L. , Dranoff , G. and Bigner , D. D.Subcutaneous vaccination with irradiated, cytokine‐producing tumor cells stimulates CD8+ cell‐mediated immunity against tumors located in the “immunologically privileged” central nervous system . Proc. Natl. Acad. Sci. USA , 93 , 10399 – 10404 ( 1996. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. ) Borden , E. C. and Sondel , P. M.Lymphokines and cytokines as cancer treatment. Immunotherapy realized . Cancer , 65 , 800 – 814 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 34. ) Kelso , A.Cytokines: structure function and synthesis . Curr. Opin. Immunol. , 2 , 215 – 225 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 35. ) Rosenberg , S. A. , Lotze , M. T. and Mule , J. J.New approaches to the immunotherapy of cancer . Ann. Intern. Med. , 108 , 853 – 864 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 36. ) Ehrke , M. J. , Verstovek , S. , Krawczyk , M. C. , Ujházy , P. , Zaleskis , G. , Maccubin , L. D. and Mihich , E.Cyclophosphamide plus tumor necrosis factor‐α chemoimmunotherapy cured mice: life‐long immunity and rejection of re‐implanted primary lymphoma . Int. J. Cancer , 63 , 463 – 471 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 37. ) Bannerji , R. , Arroyo , C. D. , Cordon‐Cardo , C. and Gilboa , E.The role of IL‐2 secreted from genetically modified tumor cells in the establishment of antitumor immunity . J. Immunol. , 152 , 2324 – 2332 ( 1994. ). [PubMed] [Google Scholar]
  • 38. ) Bevan , M. J.Antigen presentation to cytotoxic T lymphocytes in vivo . J. Exp. Med , 182 , 639 – 641 ( 1995. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. ) Huang , A. Y. C. , Golumbek , P. , Ahmadzadeh , M. , Jaffee , E. , Pardoll , D. and Levitsky , H.Role of bone marrow‐derived cells in presenting MHC class I‐restricted tumor antigens . Science , 264 , 961 – 965 ( 1994. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES